
Financings ·
Adagio Medical converts $776,111 of notes into 4,978,869 shares
A holder converted senior secured convertible notes at alternate prices set during the company's strategic review, according to an October 1 filing.
ADGM Adagio Medical Holdings, Inc.

Financings ·
A holder converted senior secured convertible notes at alternate prices set during the company's strategic review, according to an October 1 filing.
The board opened a formal process to explore alternatives that may include an acquisition, merger or other transaction, and the company has set no timetable.
The company reported stockholders' equity of negative $415,000 at June 30, 2026, below Nasdaq's $2,500,000 minimum, and must submit a compliance plan by September 28, 2026.
The company's common stock traded below $1.00 for 30 consecutive business days, and it has 180 calendar days to regain compliance.
| Line | FY2025 | FY2023 |
|---|---|---|
| Revenue | $0 | $300,000 |
| Research and development | $10.6 million | $15.4 million |
| Net income (loss) | -$25.1 million | -$36.6 million |
| Cash from operations | -$19.0 million | -$25.7 million |
| Cash and equivalents | $17.1 million | $1.4 million |
Our latest story on this, dated Oct 1, 2026: "Adagio Medical converts $776,111 of notes into 4,978,869 shares". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Aug 14, 2026: "Adagio Medical receives Nasdaq notice on stockholders' equity". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Sep 23, 2026: "Adagio Medical starts strategic review and cuts workforce". The story links the filing or release it is based on. Read the story.
Adagio Medical Holdings, Inc. trades under the ticker ADGM on NASDAQ.
Adagio Medical Holdings, Inc. is listed on NASDAQ.
Our directory records Adagio Medical Holdings, Inc. under United States.
aibio.space lists Adagio Medical Holdings, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
$0 for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Adagio Medical Holdings, Inc. reported a net loss of $25.1 million for the fiscal year ended Dec 31, 2025, and used $19.0 million of cash in operations, per its annual report to the SEC.
$10.6 million in the fiscal year ended Dec 31, 2025, per its annual report.
$7.7 million in cash at Jun 30, 2026, per its 10-Q.
Our latest story on Adagio Medical Holdings, dated Oct 1, 2026: "Adagio Medical converts $776,111 of notes into 4,978,869 shares". A holder converted senior secured convertible notes at alternate prices set during the company's strategic review, according to an October 1 filing. Source.
Our latest financing story, dated Oct 1, 2026: "Adagio Medical converts $776,111 of notes into 4,978,869 shares". A holder converted senior secured convertible notes at alternate prices set during the company's strategic review, according to an October 1 filing. Source.
From our story of Sep 23, 2026: The release does not give a cash runway or any updated operating loss for the period. Source.
Our latest distress story, dated Sep 23, 2026: "Adagio Medical starts strategic review and cuts workforce". The board opened a formal process to explore alternatives that may include an acquisition, merger or other transaction, and the company has set no timetable. Source.
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05,8.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction